Pfizer Sees Increased Cardiovascular Risk With Bextra After Bypass Surgery

Two studies on short-term use of a parecoxib/Bextra treatment regimen following coronary artery bypass graft surgery showed an increased risk of cardiovascular events. Pfizer discusses the surgery study results as part of a "Dear Health Care Professional" letter about skin reactions associated with Bextra.